Last reviewed · How we verify
Placebo oral oil
Placebo oral oil is a Small molecule drug developed by Hôpital le Vinatier. It is currently in Phase 3 development for Clinical trial control arm (therapeutic area unknown). Also known as: UX007 Placebo Oral Liquid, olive oil and chlorophyll, medium chain triglycerides, Placebo.
Placebo oral oil produces no pharmacological effect, serving as an inert control in clinical trials.
Placebo oral oil is a control intervention used in clinical trials for various conditions, including Attention Deficit Disorder With Hyperactivity and Autism. Placebo oral oil is not a vaccine component and does not induce an immune response, according to its verified mechanism.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Placebo oral oil |
|---|---|
| Also known as | UX007 Placebo Oral Liquid, olive oil and chlorophyll, medium chain triglycerides, Placebo, Matching placebo |
| Sponsor | Hôpital le Vinatier |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Placebo formulations are used in randomized controlled trials to establish baseline efficacy and safety profiles by comparison with active treatments. The oral oil vehicle itself is biologically inert and does not target any specific molecular pathway or receptor. Any observed clinical effects in placebo groups are attributed to natural disease progression, regression to the mean, or psychosomatic responses.
Approved indications
- Clinical trial control arm (therapeutic area unknown)
Common side effects
Key clinical trials
- Efficacy and Safety of an Essential Oil-Based Product System for Immune Support (NA)
- Cannabis extrAct in Oncology Patients for the Treatment of TUmor Related Symptom Burden (PHASE2)
- Randomized, Blinded, Placebo-Controlled Evaluation of BioAmicus Complete (NA)
- Cannabis and Polysubstance Use: Response Inhibition and Stress Exposure (PHASE1)
- Study of Cannabidiol in Sanfilippo Syndrome (PHASE2, PHASE3)
- Role of Omega-DEK in Childhood Apraxia of Speech (PHASE2)
- Evaluation of Oral THC and CBD in Men and Women (PHASE1)
- Marine Lipids Ease Painful TMD (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo oral oil CI brief — competitive landscape report
- Placebo oral oil updates RSS · CI watch RSS
- Hôpital le Vinatier portfolio CI
Frequently asked questions about Placebo oral oil
What is Placebo oral oil?
How does Placebo oral oil work?
What is Placebo oral oil used for?
Who makes Placebo oral oil?
Is Placebo oral oil also known as anything else?
What development phase is Placebo oral oil in?
Related
- Manufacturer: Hôpital le Vinatier — full pipeline
- Indication: Drugs for Clinical trial control arm (therapeutic area unknown)
- Also known as: UX007 Placebo Oral Liquid, olive oil and chlorophyll, medium chain triglycerides, Placebo, Matching placebo
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing